CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination With 5-AZA-2'-Deoxycytidine (Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01673217
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:33.225973+00:00
Published At: 2022-08-01T00:00:00+00:00
Record Updated At: 2022-08-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Fallopian Tube Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Primary Peritoneal Cavity Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-08-01"
protocolSection.identificationModule.nctId: "NCT01673217"
protocolSection.identificationModule.officialTitle: "A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination With 5-AZA-2\u0027-Deoxycytidine (Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.